Basel, September 25, 2023 — Novartis today confirmed plans for the 100% Spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to ...

Novartis expects the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs, will commence on Oct. 4.

On Aug. 18, Novartis issued the invitation to an Extraordinary General Meeting of Novartis shareholders, scheduled to take place on Sept. 15, in relation to the proposed 100% Spin-off of Sandoz ...

ZURICH/LONDON (Reuters) -Novartis plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday ...

Novartis is planning to spin off its generics-and-biosimilars division Sandoz and list it in Switzerland, a move that will enable Novartis to focus on innovative medicines.

Following the pattern set by other big pharmaceutical companies, Novartis plans to spin off its generics and biosimilars arm, Sandoz, into a separate company.

The planned spin-off of Sandoz comes as Novartis continues with a previously announced organizational restructuring that is expected to save the company $1.5 billion by 2024. As part of that effort, ...

Novartis AG NVS said the planned spin-off of its Sandoz unit is expected to occur on October 4, ending an era for the Swiss pharmaceutical giant in which generic and prescription drugs businesses ...

Novartis on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month.

Novartis on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month.

This follows the previously announced Novartis shareholder approval for the Spin-off of Sandoz, at the EGM on September 15 2023.